Information Provided By: 
Fly News Breaks for November 24, 2019
AGIO
Nov 24, 2019 | 19:02 EDT
Piper Jaffray analyst Tyler Van Buren reiterated an Overweight rating and $70 price target on Agios following the company's "encouraging" IDH/glioma update at the Society for Neuro-Oncology, or SNO. The analyst believes the perioperative results are "promising" given the response and disease control rates observed, and believes the "high DCR suggests that IDH inhibition is proving a meaningful, durable treatment benefit." Van Buren said that this could ultimately become a $500M opportunity that is not currently modeled.
News For AGIO From the Last 2 Days
There are no results for your query AGIO
